Linked Life Data

17353637

Source:http://linkedlifedata.com/resource/pubmed/id/17353637

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-3-13
pubmed:abstractText
Recently, new and promising antitumor agents such as TS-1, CPT-11, and taxanes have been widely used and have contributed to the survival of unresectable and recurrent gastric cancer patients. However, problems remain in the treatment for patients showing multi-drug resistance to those agents. We have experienced five patients with unresectable and recurrent gastric cancer, treated with combination therapy with bi-weekly docetaxel and 5'-deoxy-5-fluorouridine (5'-DFUR). The therapy was introduced as a 2nd, 3rd, 4th, and 6th chemotherapy regimen. Among five cases, one showed a moderate response and two exhibited stable disease, while two suffered progressive disease. Although the performance status at the start of the therapy was "2" in three cases and "1" in two cases, there were no serious adverse events in any case, and all patients were treated at an outpatient clinic. Three cases were introduced to the regimen as final treatment and survived for 209, 246, and 157 days, respectively. Combination therapy with bi-weekly docetaxel/5'-DFUR can be a promising regimen for gastric patients showing multi-drug resistance and poorer performance status.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
431-4
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Combination therapy with bi-weekly docetaxel and 5'-deoxy-5-fluorouridine for advanced gastric cancer].
pubmed:affiliation
Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.
pubmed:publicationType
Journal Article, English Abstract, Case Reports